NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-20-232 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intraoral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Funding Opportunity RFA-DA-21-009 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and (2)research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior. Of priority is research that is theoretically based and identifies specific risk and protective factors to target through prevention intervention, or research on policies that can impact adolescent ENDS use. Particularly, for prevention intervention research (e.g., school, community, and clinic-based) collaboration with stakeholders and likely program adopters is required to ensure feasibility for implementation, scalability, dissemination and sustainability. For this funding announcement, individuals as young as 12 and as old as 18 encompass the core target age range. Justification for the specific age or age range of the target population is required, including studies that propose targeting youth outside the core age range.
Funding Opportunity PAR-20-212 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators who are within 10 years of their terminal degree or residency training but who have at least two years of postdoctoral experience. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these Early Stage Investigators to develop new research directions and to position these researchers to be competitive for new research project (e.g., R01) funding. Research must be in the field of HIV/AIDS translational studies, using NHPs as preclinical models. This funding initiative encompasses all objectives of the fiscal year (FY) 2019/2020 NIH strategic plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan), including research directed towards prevention and cure of HIV infection; next-generation therapies; understanding the roles of comorbidities, coinfections and complications; and cross-cutting activities such as building capacity.
Funding Opportunity PAR-20-231 from the NIH Guide for Grants and Contracts. The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as preclinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses all objectives of the fiscal year (FY) 2019/2020 NIH strategic plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan), including research directed towards prevention and cure of HIV infection; next-generation therapies; understanding the roles of comorbidities, coinfections and complications; and cross-cutting activities such as research training and building capacity. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Notice NOT-OD-20-114 from the NIH Guide for Grants and Contracts
Notice NOT-MD-20-024 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-235 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This Funding Opportunity Announcement is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of brain function in healthy individuals or those with disorders. These mechanistic studies are expected to be responsive to the BESH FOAs https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-006.html since they are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.
Notice NOT-TR-20-029 from the NIH Guide for Grants and Contracts
Notice NOT-HL-20-797 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-20-234 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19).
Funding Opportunity RFA-AI-20-036 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV (PLWH) is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The goal of the Martin Delaney Collaboratory program is to accelerate progress towards developing strategies to achieve either eradication of HIV infection from the body or a sustained viral remission, as defined by sustained viral suppression following cessation of antiretroviral therapy. Funded projects under this FOA will be expected to expand the knowledge base on HIV latency and persistence in pediatric populations, design and evaluate innovative cure strategies, develop and evaluate assays and other modalities to accurately characterize HIV reservoirs and translate findings to the clinical settings. This funding opportunity will target perinatally infected children and adolescents up to 24 years of age with a primary focus on early treated children.
Funding Opportunity RFA-AI-20-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV.
Funding Opportunity RFA-AG-21-023 from the NIH Guide for Grants and Contracts. The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR Funding Opportunity Announcement (FOA) provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.
Funding Opportunity RFA-HL-21-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support hybrid effectiveness-implementation trials for heart, lung, blood, and sleep (HLBS) diseases in the inpatient setting. NHLBI is seeking applications that propose a trial testing an implementation strategy (or strategies) that was developed utilizing an implementation research framework and that aims to increase implementation of an evidence-based practice(s). This FOA intends to support applications that propose a multidisciplinary research team that includes expertise in inpatient clinical research, implementation research, and biostatistics. Any applicant proposing a trial that meets the requirements of this FOA is eligible to apply, regardless of participation in Planning Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U34) (RFA-HL-18-018).
Notice NOT-MH-20-055 from the NIH Guide for Grants and Contracts
Notice NOT-HD-20-018 from the NIH Guide for Grants and Contracts
Notice NOT-HL-20-796 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-121 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-120 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-119 from the NIH Guide for Grants and Contracts